Decoy Therapeutics financials
$2.04−11.90%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $227.6K | $0.00 |
| Gross profit | $227.6K | $0.00 |
| Gross margin | 100.0% | — |
| Operating income | -$2.4M | -$2.3M |
| Net income | -$2.4M | -$2.2M |
| Net margin | −1042.8% | — |
| Diluted EPS | $-4.46 | $-4.18 |
| EBITDA | -$2.4M | -$2.3M |
| Operating cash flow | -$2.7M | -$2.9M |
| Free cash flow | -$2.7M | -$2.9M |
| Diluted shares | 0.5M | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $8.3M | $7.8M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $9.0M | $8.4M |
| Total liabilities | $4.7M | $4.5M |
| Shareholders' equity | $4.3M | $3.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology